{"id":533256,"date":"2021-09-01T08:04:04","date_gmt":"2021-09-01T12:04:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/"},"modified":"2021-09-01T08:04:04","modified_gmt":"2021-09-01T12:04:04","slug":"longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/","title":{"rendered":"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MIAMI, Sept.  01, 2021  (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN) (&#8220;Longeveron&#8221; or &#8220;Company&#8221;),\u00a0a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virtually at the H.C. Wainwright 23rd Annual Global Investor Conference.<\/p>\n<p align=\"justify\">The corporate presentation will be available for on-demand viewing beginning September 13, 2021 at 7:00 a.m. EDT via the Investors &amp; Media section of the Company website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.<\/p>\n<p>\n        <strong>About Longeveron Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company\u2019s lead investigational product is the LOMECEL-B\u2122 cell-based therapy product (\u201cLomecel-B\u201d), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer\u2019s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company\u2019s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=33q1HyZN6BfNMImQEWEbaqkidBgCZvyVQJDOWnUekOHcWyAK-FJbuzhvQ1Ps0rboO9xW1w52gsLvdY2Pa9AxJbnrS0d_Qr5vqQ_0iohjC74=\" rel=\"nofollow noopener\" target=\"_blank\">www.longeveron.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Brendan Payne<br \/>Stern Investor Relations<br \/>Office Direct: 212-698-8695 |Office Main: 212-362-1200<br \/>brendan.payne@sternir.com | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vX8aFFpOZOqeaTHkXSYmhLE13e8qf-8-CDIx_QxuD7zPk8q6PmcsM68T9W5a9GQuN8LEXFSqzzg-mKKXxNjndQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.sternir.com<\/a><\/p>\n<p>\n        <u>Source: Longeveron Inc<\/u><br \/>\n        <br \/>\n        <u>Source: LGVN<\/u>\n      <\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWVhMTQyZjYtNGQ0Ni00NDM0LWI0YmEtYzE3ZGNjZTlkZTZjLTEyMTg2MTM=\/tiny\/Longeveron.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MIAMI, Sept. 01, 2021 (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN) (&#8220;Longeveron&#8221; or &#8220;Company&#8221;),\u00a0a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virtually at the H.C. Wainwright 23rd Annual Global Investor Conference. The corporate presentation will be available for on-demand viewing beginning September 13, 2021 at 7:00 a.m. EDT via the Investors &amp; Media section of the Company website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company\u2019s lead investigational product is the LOMECEL-B\u2122 cell-based therapy product (\u201cLomecel-B\u201d), &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533256","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, Sept. 01, 2021 (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN) (&#8220;Longeveron&#8221; or &#8220;Company&#8221;),\u00a0a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virtually at the H.C. Wainwright 23rd Annual Global Investor Conference. The corporate presentation will be available for on-demand viewing beginning September 13, 2021 at 7:00 a.m. EDT via the Investors &amp; Media section of the Company website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company\u2019s lead investigational product is the LOMECEL-B\u2122 cell-based therapy product (\u201cLomecel-B\u201d), &hellip; Continue reading &quot;Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-01T12:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference\",\"datePublished\":\"2021-09-01T12:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/\",\"name\":\"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=\",\"datePublished\":\"2021-09-01T12:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference - Market Newsdesk","og_description":"MIAMI, Sept. 01, 2021 (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN) (&#8220;Longeveron&#8221; or &#8220;Company&#8221;),\u00a0a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virtually at the H.C. Wainwright 23rd Annual Global Investor Conference. The corporate presentation will be available for on-demand viewing beginning September 13, 2021 at 7:00 a.m. EDT via the Investors &amp; Media section of the Company website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company\u2019s lead investigational product is the LOMECEL-B\u2122 cell-based therapy product (\u201cLomecel-B\u201d), &hellip; Continue reading \"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-01T12:04:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference","datePublished":"2021-09-01T12:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/"},"wordCount":291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/","name":"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=","datePublished":"2021-09-01T12:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODIzOSM0MzgzNjExIzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533256"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533256\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}